Endometriosis Treatment Composition with Delayed-Release Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for endometriosis, such as hormonal therapies and non-conventional herbal remedies, offer only partial relief from symptoms and are associated with side effects, failing to provide a permanent solution for pain reduction and disease recurrence.
Innovation Solution
A composition comprising N-acetyl cysteine, alpha-lipoic acid, and bromelain, formulated with a delayed-release gastro-resistant coating, which synergistically reduces endometriotic endothelial cell proliferation and inflammation, thereby addressing the disease's pathogenic mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hormonal treatments (GnRH agonists, danazol, progestins) are used to treat endometriosis, then pain symptoms are reduced in the short term, but side effects occur and the disease recurs after treatment cessation
Solution Approach 1:
The patent combines three distinct compounds (N-acetyl cysteine, alpha-lipoic acid, and bromelain) into a composite formulation that targets multiple pathogenic mechanisms of endometriosis simultaneously - oxidative stress, inflammation, and prostaglandin synthesis - thereby achieving effective symptom relief without the severe side effects of conventional hormonal therapies
2Reliability
If conventional hormonal treatments are used to reduce endometriosis lesion size, then partial effectiveness is achieved, but the treatment does not provide permanent solution and disease recurs
Solution Approach 1:
The composition addresses the root causes of endometriosis progression by inhibiting oxidative stress pathways and inflammatory mediators before they can cause significant lesion growth and recurrence, thereby providing longer-lasting symptom relief and reducing the risk of disease recurrence after treatment cessation
3Ease of operation
If non-conventional herbal remedies are used to treat endometriosis, then some symptom relief is provided, but the treatment is not effective in permanently curing the disease
Solution Approach 1:
The patent employs compounds with established safety profiles (N-acetyl cysteine, alpha-lipoic acid, bromelain) that are well-tolerated by patients, while optimizing their concentrations and combinations to achieve curative effectiveness by targeting multiple pathogenic pathways simultaneously, thereby bridging the gap between patient tolerance and curative effectiveness
4Device complexity
If single-agent treatments are used for endometriosis, then the treatment mechanism is simple, but the effectiveness in reducing both pain and lesion progression is limited
Solution Approach 1:
The patent merges three complementary compounds into a single formulation where N-acetyl cysteine addresses oxidative stress and glutathione depletion, alpha-lipoic acid provides additional antioxidant support and anti-inflammatory effects, and bromelain inhibits prostaglandin synthesis and reduces inflammation, creating a synergistic effect that surpasses the effectiveness of any single agent alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces the progression of endometriotic lesions and associated pain symptoms, offering a well-tolerated alternative with fewer side effects and improved bioavailability compared to conventional treatments.
Implementation Method 1
a composition comprising N-acetyl cysteine, alpha-lipoic acid, and bromelain, which synergistically reduces endometriotic endothelial cell proliferation and inflammation
Implementation Method 2
The composition effectively reduces the progression of endometriotic lesions and associated pain symptoms
Implementation Method 3
formulated with a delayed-release gastro-resistant coating, which synergistically reduces endometriotic endothelial cell proliferation and inflammation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a new composition, preferably with delayed release, containing N-acetyl cysteine, alpha-lipoic acid, and bromelain, in addition to the use thereof in the treatment of endometriosis, dysmenorrhoea, and/or pelvic pain.